Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Expression of CD44 variants in osteosarcoma.

M Kuryu1, T Ozaki, K Nishida

  • 1Department of Orthopaedic Surgery, Faculty of Medicine, Okayama University Medical School, Okayama 700-8558, Japan.

Journal of Cancer Research and Clinical Oncology
|October 29, 1999
PubMed
Summary

CD44 standard (CD44H) and variant exon products were analyzed in osteosarcoma. CD44v6 expression is linked to poorer metastasis-free survival and is a significant prognostic factor in osteosarcoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Landscape of ultra-rare sarcomas: a nationwide study for epidemiology and prognosis.

ESMO open·2025
Same author

Translocation in bone and soft tissue sarcomas: a comprehensive epidemiological investigation.

ESMO open·2024
Same author

The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology.

ESMO open·2024
Same author

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same author

Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>☆</sup>.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunohistochemistry

Background:

  • CD44, a transmembranous glycoprotein, exists in standard (CD44H) and variant forms generated by alternative splicing.
  • CD44 expression is implicated in tumor differentiation, invasion, and metastasis.
  • Osteosarcoma is a primary bone malignancy with significant metastatic potential.

Purpose of the Study:

  • To investigate the expression of CD44 standard and variant isoforms in osteosarcoma specimens.
  • To analyze the correlation between CD44 expression and clinical outcomes, specifically metastasis-free survival.
  • To identify CD44 isoforms as potential prognostic markers in osteosarcoma.

Main Methods:

  • Immunochemical analysis of 44 osteosarcoma specimens from 39 patients.

Related Experiment Videos

  • Assessment of CD44H and variant exon products (CD44v3, v4, v5, v6, v7, v9, v10) expression.
  • Statistical analysis including Kaplan-Meier survival curves and Cox proportional-hazard model.

    • Main Results:

    • CD44H, v3, v4, v5, v6, v7, v9, and v10 were expressed in 85%, 49%, 54%, 59%, 46%, 5%, 28%, and 10% of specimens, respectively.
    • A significant decrease in 5-year metastasis-free survival was observed in CD44v6-positive cases (24%) compared to CD44v6-negative cases (58%) (P=0.046).
    • Multivariate analysis identified CD44v6 expression and chemotherapy as significant prognostic factors.

    Conclusions:

    • Overexpression of CD44 isoforms containing the v6 variant is associated with a poor prognosis in osteosarcoma patients.
    • CD44v6 expression serves as a valuable prognostic indicator for metastasis-free survival in osteosarcoma.
    • Targeting CD44v6 may offer potential therapeutic strategies for improving outcomes in osteosarcoma.